FDA clears IND for Mineralys' lorundrostat Phase 2 trial in obstructive sleep apnea with hypertension

Mineralys Therapeutics, Inc.

FDA cleared IND for Phase 2 trial of lorundrostat in moderate-to-severe OSA with hypertension.
Trial to evaluate effect on apnea-hypopnea frequency & nocturnal hypertension; initiation expected Q1 2025.
Approximately 40 subjects, placebo-controlled crossover design at up to 40 sites.
Cash, cash equivalents & investments expected to fund operations through Q1 2026.
This is the third targeted indication for lorundrostat, following hypertension and CKD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.